Ilmarinen Mutual Pension Insurance Co purchased a new position in shares of Kenvue Inc. (NYSE:KVUE – Free Report) in the 4th quarter, Holdings Channel reports. The firm purchased 280,000 shares of the company’s stock, valued at approximately $4,830,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Cornerstone Planning Group LLC grew its holdings in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue during the 4th quarter worth about $26,000. Golden State Wealth Management LLC boosted its position in shares of Kenvue by 150.1% during the 3rd quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after acquiring an additional 1,190 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its position in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after acquiring an additional 1,027 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
Insider Activity at Kenvue
In related news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.59% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Read Our Latest Research Report on KVUE
Kenvue Stock Down 2.0%
Shares of NYSE KVUE opened at $17.29 on Friday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $23.90. The stock has a market capitalization of $33.19 billion, a price-to-earnings ratio of 20.34, a price-to-earnings-growth ratio of 1.34 and a beta of 0.55. The firm has a 50-day moving average price of $17.40 and a 200 day moving average price of $17.46. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same quarter in the prior year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.
Kenvue Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were given a $0.2075 dividend. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Wednesday, May 13th. Kenvue’s dividend payout ratio is currently 97.65%.
Kenvue Company Profile
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Recommended Stories
- Five stocks we like better than Kenvue
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
